EXAI

Investor Moves

Name	Value	Action	Change	Price	Current Price
Baillie GiffordInvestor $-18.8M ExitQ4 2024 $19M -- --
Ken GriffinCitadel Advisors $-665.6K ExitQ4 2024 $666k -- --
Baillie GiffordInvestor $-3.6M TrimQ3 2024 $3.6M -- --
Ken GriffinCitadel Advisors $303.0K AddQ3 2024 $303k -- --
Baillie GiffordInvestor $-26.2M ExitQ2 2024 $26M -- --
Baillie GiffordInvestor $-3.7M TrimQ2 2024 $3.7M -- --

Trade EXAI

About Exscientia plc

Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.

CEO: David Hallett
IPO Date: Oct 1, 2021

Market Data

High: $4.84
Low: $4.84
Volume: 0
Avg Volume: 707.2K
52W High: $4.84
52W Low: $4.84

Valuation

Market Cap: $633M
Enterprise Value: $240M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-144M
Revenue: $20M
Net Income: $-146M
Cash: $258M
Debt: $19M

Events

EarningsNov 8

EPS est. -0.09 · actual -0.52